Dupilumab in real-world pediatric asthma: Enhanced control and quality of life for children and caregivers.

World Allergy Organ J · 2026 · PMC12854029 · PMID 41623400

Europe PMC DOI

hedged sentence

0.5733

closest p · 11.5× alpha

0.5733

boldest claim

The sentences

did not reach statistical significancep = 0.5733not close (p > 0.1)

At week 24, a mean difference of +0.12 points favoring dupilumab (3.81 vs 3.69) was observed, which did not reach statistical significance (p = 0.5733).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.